AVEO Oncology Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 115

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $566M

AVEO Oncology General Information

Description

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Contact Information

Formerly Known As
GenPath Pharmaceuticals
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • One Marina Park Drive
  • 12th Floor
  • Boston, MA 02210
  • United States
+1 (857)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • One Marina Park Drive
  • 12th Floor
  • Boston, MA 02210
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVEO Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Merger/Acquisition 19-Jan-2023 $566M Completed Generating Revenue
16. 2PO 16-Aug-2018 Completed Generating Revenue
15. Secondary Transaction - Open Market Completed Generating Revenue
14. 2PO 29-Mar-2017 Completed Profitable
13. PIPE 13-May-2016 Completed Profitable
12. Secondary Transaction - Open Market 14-Feb-2014 Completed Profitable
11. Secondary Transaction - Open Market 01-Jan-2014 Completed Profitable
10. PIPE 31-Dec-2013 Completed Profitable
9. Secondary Transaction - Open Market 01-Jan-2011 $262M Completed Profitable
8. IPO 12-Mar-2010 $81M $262M Completed Profitable
To view AVEO Oncology’s complete valuation and funding history, request access »

AVEO Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines
Pharmaceuticals
Boston, MA
115 As of 2021

Cambridge, MA
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVEO Oncology Competitors (44)

One of AVEO Oncology’s 44 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Incyte Formerly VC-backed Wilmington, DE
Agenus Formerly VC-backed Lexington, MA
Merck & Co. Corporation Rahway, NJ
Amgen Formerly PE-Backed Thousand Oaks, CA
You’re viewing 5 of 44 competitors. Get the full list »

AVEO Oncology Patents

AVEO Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024352029-A1 Methods of reducing weight loss using anti-gdf15 antibodies Pending 27-Sep-2023
EP-4784617-A1 Methods of reducing weight loss using anti-gdf15 antibodies Pending 27-Sep-2023
WO-2025072516-A1 Methods of reducing weight loss using anti-gdf15 antibodies Inactive 27-Sep-2023
WO-2023136837-A1 Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc) Inactive 14-Jan-2022
AU-2021474103-A1 Combination therapy for treatment of cancer Pending 18-Nov-2021 G01N33/57557
To view AVEO Oncology’s complete patent history, request access »

AVEO Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVEO Oncology Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bessemer Venture Partners Venture Capital Minority
Biogen Corporation Minority
FBR & Company Investment Bank Minority
Flagship Pioneering Venture Capital Minority
GE Capital Lender/Debt Provider Minority
You’re viewing 5 of 19 investors. Get the full list »

AVEO Oncology ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view AVEO Oncology’s complete esg history, request access »

AVEO Oncology FAQs

  • When was AVEO Oncology founded?

    AVEO Oncology was founded in 2001.

  • Where is AVEO Oncology headquartered?

    AVEO Oncology is headquartered in Boston, MA.

  • What is the size of AVEO Oncology?

    AVEO Oncology has 115 total employees.

  • What industry is AVEO Oncology in?

    AVEO Oncology’s primary industry is Pharmaceuticals.

  • Is AVEO Oncology a private or public company?

    AVEO Oncology is a Private company.

  • What is the current valuation of AVEO Oncology?

    The current valuation of AVEO Oncology is .

  • What is AVEO Oncology’s current revenue?

    The current revenue for AVEO Oncology is .

  • How much funding has AVEO Oncology raised over time?

    AVEO Oncology has raised $306M.

  • Who are AVEO Oncology’s investors?

    Bessemer Venture Partners, Biogen, FBR & Company, Flagship Pioneering, and GE Capital are 5 of 19 investors who have invested in AVEO Oncology.

  • Who are AVEO Oncology’s competitors?

    Alnylam Pharmaceuticals, Incyte, Agenus, Merck & Co., and Amgen are some of the 44 competitors of AVEO Oncology.

  • When was AVEO Oncology acquired?

    AVEO Oncology was acquired on 19-Jan-2023.

  • Who acquired AVEO Oncology?

    AVEO Oncology was acquired by LG Chem.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process